Clinical Trial Update: Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating firmonertinib in combination with intrathecal injection for EGFR-mutant non-small cell lung cancer with leptomeningeal metastases is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Firmonertinib (firmonertinib)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Leptomeningeal Metastasis, NSCLC | Phase 4 | Status: RECRUITING